Multicenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation
Lerman J, Green C, Molina M, Maharaj V, Ortega‐Legaspi J, Sen S, Flattery M, Maziarz E, Shah K, Martin C, Alexy T, Shah P, Morris A, DeVore A, Cole R. Multicenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation. Clinical Transplantation 2023, 37: e15065. PMID: 37392192, PMCID: PMC10592402, DOI: 10.1111/ctr.15065.Peer-Reviewed Original ResearchConceptsAcute cellular rejectionCardiac allograft vasculopathyUniversal prophylaxisPreemptive therapyHeart transplantHT recipientsGrade 2RIntermediate riskCMV-related complicationsIncidence of leukopeniaPre-emptive therapyAnti-CMV therapyEnd-organ diseaseInitiation/escalationAllograft vasculopathyCellular rejectionCMV DNAemiaCMV preventionGraft outcomeHeart transplantationCMV infectionSecondary outcomesPrimary outcomeProphylaxis strategiesSuch patients